Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
Status:
Withdrawn
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized pilot study to assess the effect on bone mineral density
(BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to
dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.